Virbac

Valuation Analysis

About the Company

Virbac en bref

Virbac (VIRP.PA) is currently trading at 329,50 € with a market capitalization of 2,4 Md €. The trailing P/E ratio stands at 18.31x, with a forward P/E of 14.52x. The 52-week range spans from 296,00 € to 389,50 €; the current price is 15.4% below the yearly high. Year-over-year revenue growth stands at +4.6%. The net profit margin stands at 10.3%.

💰 Dividende

Virbac pays an annual dividend of 1,45 € per share, representing a yield of 0.44%. The payout ratio stands at 8.06%.

📊 Avis des analystes

8 analystes évaluent Virbac (VIRP.PA) au consensus : Acheter. L'objectif de cours moyen est de 412,88 €, soit un potentiel de +25.3% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 368,00 € à 440,00 €.

Virbac : la thèse d'investissement en détail

Virbac (VIRP.PA) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 35.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 66.69%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 25.3% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 4.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valorisation en contexte

At a PEG of 3.27, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 14.52x is meaningfully below the trailing 18.31x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 25.3% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Virbac?

Compare top-rated brokers — low fees, trusted providers, fully regulated.